Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sinovac Biotech ( (SVA) ) has provided an announcement.
On January 16, 2025, Sinovac Biotech Ltd. announced a Privy Council judgment validating the election of a new board proposed by shareholders during the 2018 Annual General Meeting. The ruling invalidates the company’s Rights Agreement and is set to become effective after a court order. Sinovac’s outgoing board is committed to a smooth transition, emphasizing the company’s history of significant shareholder value creation, highlighted by its substantial contribution to the global COVID-19 vaccine effort with 2.9 billion doses delivered worldwide.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines. The company’s product portfolio includes vaccines for COVID-19, hepatitis A, influenza, and polio, among others. Sinovac has played a significant role in the global COVID-19 pandemic response with its CoronaVac® vaccine, which is approved in over 60 countries.
YTD Price Performance: 0.0%
Average Trading Volume: 8,227
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $460.3M
Find detailed analytics on SVA stock on TipRanks’ Stock Analysis page.
